nadifloxacin has been researched along with Acne in 20 studies
nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "1% gel plus nadifloxacin 1% cream (combination therapy) compared with adapalene gel (monotherapy) during 12-week treatment of acne vulgaris." | 9.17 | Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris. ( Furukawa, F; Ito, T; Noguchi, N; Shimada, S; Takigawa, M; Tokura, Y, 2013) |
| "To compare the dermal irritation produced by an anti-acne cream containing 1% nadifloxacin with that produced by additional treatment with four different topical anti-acne products in a 21-day open application test in 40 healthy volunteers." | 9.16 | Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents. ( Neumeister, C; Schwantes, U; Wilhelm, D; Wilhelm, KP; Zsolt, I, 2012) |
| "At final visits, inflammatory acne lesions were reduced by 70% on nadifloxacin-treated skin and increased by 13." | 9.15 | Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. ( Jung, JY; Kwon, HH; Suh, DH; Yeom, KB; Yoon, MY, 2011) |
| " To confirm the efficacy and safety of adapalene gel and nadifloxacin cream in the treatment of Japanese patients with acne vulgaris, a total of 50 patients were randomized to the two groups, the combination therapy and the adapalene monotherapy, and each therapy was tested for 8 weeks." | 9.15 | Efficacy of combined topical treatment of acne vulgaris with adapalene and nadifloxacin: a randomized study. ( Fukamachi, K; Kobayashi, M; Nakagawa, T; Nakamura, M; Tokura, Y, 2011) |
| "The objective of the present study was to develop a nanocarrier based formulation of nadifloxacin and to investigate its in vitro antimicrobial effect against Propionibacterium acnes." | 7.77 | Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment. ( Agarwal, SP; Ahuja, A; Ali, J; Baboota, S; Choudhry, R; Kumar, A, 2011) |
| "To evaluate the possible involvement of potential anti-inflammatory activity of nadifloxacin in its therapeutic effect on inflammatory acne, we examined the effects of nadifloxacin, in comparison with other antibiotics used to treat acne vulgaris, on cytokine production by human peripheral blood mononuclear cells (PBMC) and keratinocytes." | 7.73 | Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. ( Kikuchi, M; Kitagaki, H; Kitazawa, T; Kuwahara, K; Tsukamoto, T, 2005) |
| "Acne vulgaris is characteristic of excess sebum production and the induction of inflammatory reactions, for example, the augmentation of cytokine, prostaglandin (PG) and matrix metalloproteinase (MMP) production in sebaceous glands and pilosebaceous units." | 5.38 | Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E(2) and promatrix metalloproteinase-2 in hamster sebocytes. ( Ito, A; Noguchi, N; Sasatsu, M; Sato, T; Shirane, T, 2012) |
| "A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years." | 5.37 | A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory ( Danno, K; Fujimoto, N; Tanaka, T; Uenishi, T; Wakabayashi, M, 2011) |
| "To compare the dermal irritation produced by an anti-acne cream containing 1% nadifloxacin with that produced by additional treatment with four different topical anti-acne products in a 21-day open application test in 40 healthy volunteers." | 5.16 | Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents. ( Neumeister, C; Schwantes, U; Wilhelm, D; Wilhelm, KP; Zsolt, I, 2012) |
| "At final visits, inflammatory acne lesions were reduced by 70% on nadifloxacin-treated skin and increased by 13." | 5.15 | Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. ( Jung, JY; Kwon, HH; Suh, DH; Yeom, KB; Yoon, MY, 2011) |
| "Nadifloxacin is a potent, broad-spectrum, quinolone agent approved for topical use in acne vulgaris and skin infections in Japan." | 4.83 | Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. ( Appelbaum, PC; Jacobs, MR, 2006) |
| "The objective of the present study was to develop a nanocarrier based formulation of nadifloxacin and to investigate its in vitro antimicrobial effect against Propionibacterium acnes." | 3.77 | Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment. ( Agarwal, SP; Ahuja, A; Ali, J; Baboota, S; Choudhry, R; Kumar, A, 2011) |
| "To evaluate the possible involvement of potential anti-inflammatory activity of nadifloxacin in its therapeutic effect on inflammatory acne, we examined the effects of nadifloxacin, in comparison with other antibiotics used to treat acne vulgaris, on cytokine production by human peripheral blood mononuclear cells (PBMC) and keratinocytes." | 3.73 | Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. ( Kikuchi, M; Kitagaki, H; Kitazawa, T; Kuwahara, K; Tsukamoto, T, 2005) |
| "To examine the potential anti-androgenic activity of anti-acne therapeutic agents, nadifloxacin (NDFX), RXM, all-trans retinoic acid (atRA), and glycolic acid (GA), we carried out the transient transfection assays using the CV-1 cells as a more sensitive assay system." | 3.72 | Modulation of androgen receptor transcriptional activity by anti-acne reagents. ( Inui, S; Itami, S; Nakao, T, 2004) |
| "acnes was compared before and after treatment, the posttreatment P." | 2.67 | Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. ( Akamatsu, H; Asada, Y; Kawabata, S; Kurokawa, I; Nishijima, S, 1991) |
| "Therefore, acne is not a simple infection with Propionibacterium acnes, but subsequent inflammatory changes are the nature of acne." | 2.44 | [Anti-microbial therapies for acne vulgaris: anti-inflammatory actions of anti-microbial drugs and their effectiveness]. ( Murata, K; Tokura, Y, 2007) |
| "Acne vulgaris is a multifactorial skin disease associated with the colonization of Propionibacterium acnes." | 1.43 | Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. ( Ghosh, S; Gupta, T; Kaur, SP; Sadhasivam, S; Saini, S; Sardana, K; Sengupta, S; Sinha, M, 2016) |
| "Acne vulgaris is characteristic of excess sebum production and the induction of inflammatory reactions, for example, the augmentation of cytokine, prostaglandin (PG) and matrix metalloproteinase (MMP) production in sebaceous glands and pilosebaceous units." | 1.38 | Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E(2) and promatrix metalloproteinase-2 in hamster sebocytes. ( Ito, A; Noguchi, N; Sasatsu, M; Sato, T; Shirane, T, 2012) |
| "A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years." | 1.37 | A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory ( Danno, K; Fujimoto, N; Tanaka, T; Uenishi, T; Wakabayashi, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nenoff, P | 1 |
| Koch, D | 1 |
| Krüger, C | 1 |
| Neumeister, C | 2 |
| Götz, MR | 1 |
| Schwantes, U | 2 |
| Bödeker, RH | 1 |
| Borelli, C | 1 |
| Takigawa, M | 1 |
| Tokura, Y | 3 |
| Shimada, S | 1 |
| Furukawa, F | 1 |
| Noguchi, N | 3 |
| Ito, T | 1 |
| Nakajima, A | 1 |
| Ikeda, F | 1 |
| Kanayama, S | 1 |
| Okamoto, K | 1 |
| Matsumoto, T | 1 |
| Ishii, R | 1 |
| Fujikawa, A | 1 |
| Takei, K | 1 |
| Kawashima, M | 1 |
| Sadhasivam, S | 1 |
| Sinha, M | 1 |
| Saini, S | 1 |
| Kaur, SP | 1 |
| Gupta, T | 1 |
| Sengupta, S | 1 |
| Ghosh, S | 1 |
| Sardana, K | 1 |
| Nakase, K | 1 |
| Sakuma, Y | 1 |
| Nakaminami, H | 1 |
| Tunca, M | 1 |
| Akar, A | 1 |
| Ozmen, I | 1 |
| Erbil, H | 1 |
| Jung, JY | 1 |
| Kwon, HH | 1 |
| Yeom, KB | 1 |
| Yoon, MY | 1 |
| Suh, DH | 1 |
| Kumar, A | 1 |
| Agarwal, SP | 1 |
| Ahuja, A | 1 |
| Ali, J | 1 |
| Choudhry, R | 1 |
| Baboota, S | 1 |
| Wakabayashi, M | 1 |
| Fujimoto, N | 1 |
| Uenishi, T | 1 |
| Danno, K | 1 |
| Tanaka, T | 1 |
| Kobayashi, M | 1 |
| Nakagawa, T | 1 |
| Fukamachi, K | 1 |
| Nakamura, M | 1 |
| Wilhelm, KP | 1 |
| Wilhelm, D | 1 |
| Zsolt, I | 1 |
| Sato, T | 1 |
| Shirane, T | 1 |
| Sasatsu, M | 1 |
| Ito, A | 1 |
| Inui, S | 1 |
| Nakao, T | 1 |
| Itami, S | 1 |
| Kuwahara, K | 1 |
| Kitazawa, T | 1 |
| Kitagaki, H | 1 |
| Tsukamoto, T | 1 |
| Kikuchi, M | 1 |
| Jacobs, MR | 1 |
| Appelbaum, PC | 1 |
| Murata, K | 1 |
| Bojar, RA | 1 |
| Hittel, N | 1 |
| Cunliffe, WJ | 1 |
| Holland, KT | 1 |
| Vogt, K | 2 |
| Hahn, H | 2 |
| Hermann, J | 2 |
| Haustein, UF | 2 |
| Blume, U | 2 |
| Gollnick, H | 2 |
| Orfanos, CE | 2 |
| Kurokawa, I | 1 |
| Akamatsu, H | 1 |
| Nishijima, S | 1 |
| Asada, Y | 1 |
| Kawabata, S | 1 |
2 reviews available for nadifloxacin and Acne
| Article | Year |
|---|---|
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Animals; Anti-Infective Agents; Clinical | 2006 |
[Anti-microbial therapies for acne vulgaris: anti-inflammatory actions of anti-microbial drugs and their effectiveness].
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clindamycin | 2007 |
7 trials available for nadifloxacin and Acne
| Article | Year |
|---|---|
Clinical and bacteriological evaluation of adapalene 0.1% gel plus nadifloxacin 1% cream versus adapalene 0.1% gel in patients with acne vulgaris.
Topics: Acne Vulgaris; Adapalene; Adolescent; Adult; Child; Dermatologic Agents; Drug Resistance, Bacterial; | 2013 |
Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Bacterial Agents; Erythromycin; Fe | 2010 |
Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Emollients; Facial Dermatoses; Female; Fl | 2011 |
Efficacy of combined topical treatment of acne vulgaris with adapalene and nadifloxacin: a randomized study.
Topics: Acne Vulgaris; Adapalene; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Child; | 2011 |
Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents.
Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Dermatologic Agent | 2012 |
Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin.
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Drug | 1995 |
Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base.
Topics: Acne Vulgaris; Administration, Cutaneous; Adolescent; Adult; Anti-Bacterial Agents; Colony Count, Mi | 1991 |
11 other studies available for nadifloxacin and Acne
| Article | Year |
|---|---|
Activity of nadifloxacin and three other antimicrobial agents against Cutibacterium acnes isolated from patients with acne vulgaris.
Topics: Acne Vulgaris; Anti-Bacterial Agents; Anti-Infective Agents; Fluoroquinolones; Humans; Microbial Sen | 2021 |
Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris.
Topics: Acne Vulgaris; Aminopyridines; Anti-Infective Agents; Asian People; Fluoroquinolones; Humans; Microb | 2016 |
Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes.
Topics: Acne Vulgaris; Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Substitution; Drug Therapy, C | 2016 |
Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Topics: Acne Vulgaris; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; DN | 2016 |
Preparation, characterization, and in vitro antimicrobial assessment of nanocarrier based formulation of nadifloxacin for acne treatment.
Topics: Acne Vulgaris; Anti-Infective Agents; Chemistry, Pharmaceutical; Culture Media; Drug Carriers; Drug | 2011 |
A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory
Topics: Acne Vulgaris; Anti-Inflammatory Agents; Biopsy; Cefozopran; Cephalosporins; Colitis, Ulcerative; Da | 2011 |
Novel anti-acne actions of nadifloxacin and clindamycin that inhibit the production of sebum, prostaglandin E(2) and promatrix metalloproteinase-2 in hamster sebocytes.
Topics: Acne Vulgaris; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Cells, Cultured; | 2012 |
Modulation of androgen receptor transcriptional activity by anti-acne reagents.
Topics: Acne Vulgaris; Androgen Antagonists; Animals; Cell Line; Dermatologic Agents; Fluoroquinolones; Glyc | 2004 |
Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes.
Topics: Acne Vulgaris; Administration, Topical; Anti-Bacterial Agents; Cells, Cultured; Clindamycin; Coryneb | 2005 |
Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris.
Topics: Acne Vulgaris; Anti-Infective Agents; Bacteria; Fluoroquinolones; Humans; Microbial Sensitivity Test | 1995 |
Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris.
Topics: Acne Vulgaris; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Fluoroqui | 1992 |